Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2021 Feb 9;11(2):251.
doi: 10.3390/biom11020251.

The Role of Interferons in the Pathogenesis of Sjögren's Syndrome and Future Therapeutic Perspectives

Affiliations
Review

The Role of Interferons in the Pathogenesis of Sjögren's Syndrome and Future Therapeutic Perspectives

Nicoletta Del Papa et al. Biomolecules. .

Abstract

There is a great deal of evidence pointing to interferons (IFNs) as being key cytokines in the pathogenesis of different systemic autoimmune diseases, including primary Sjögren's syndrome (pSS). In this disease, a large number of studies have shown that an overexpression of type I IFN, the 'so-called' type I IFN signature, is present in peripheral blood mononuclear cells, and that this finding is associated with the development of systemic extra-glandular manifestations, and a substantial production of autoantibodies and inflammatory cytokines. In contrast, the absence or a milder expression of type I IFN signature and low level of inflammatory cytokines characterizes patients with a different clinical phenotype, where the disease is limited to glandular involvement and often marked by the presence of widespread pain and depression. The role of type II (IFNγ) in this subset of pSS patients, together with the potentially related activation of completely different immunological and metabolic pathways, are emerging issues. Expression of both types of IFNs has also been shown in target tissues, namely in minor salivary glands where a predominance of type II IFN signature appeared to have a certain association with the development of lymphoma. In view of the role played by IFN overexpression in the development and progression of pSS, inhibition or modulation of IFN signaling has been regarded as a potential target for the therapeutic approach. A number of therapeutic compounds with variable mechanisms of action have been tested or are under consideration for the treatment of patients with pSS.

Keywords: Sjögren’s syndrome; target therapies; type I interferon; type II interferon.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Schematic view of the main steps of type I, type II, and type III Interferon-IFN pathways, from the specific receptor link to IFN-stimulated genes (ISGs) activation. For all the abbreviations, see text. Credit: modified from Smart Servier Medical Art (https://smart.servier.com (accessed on 18 January 2021)).

Similar articles

Cited by

References

    1. Moutsopoulos H.M. Sjögren’s syndrome: A forty-year scientific journey. J. Autoimmun. 2014;51:1–9. doi: 10.1016/j.jaut.2014.01.001. - DOI - PubMed
    1. Vitali C., Del Papa N. Pain in primary Sjögren’s syndrome. Best Pract. Res. Clin. Rheumatol. 2015;29:63–70. doi: 10.1016/j.berh.2015.05.002. - DOI - PubMed
    1. Nakamura H., Shimizu T., Kawakami A. Role of viral infections in the pathogenesis of Sjögren’s syndrome: Different characteristics of Epstein-Barr virus and HTLV-1. J. Clin. Med. 2020;9:1459. doi: 10.3390/jcm9051459. - DOI - PMC - PubMed
    1. Utomo S.W., Putri J.F. Infections as risk factor of Sjögren’s syndrome. Open Access Rheumatol. 2020;12:257–266. doi: 10.2147/OARRR.S276727. - DOI - PMC - PubMed
    1. Vitali C. Immunopathologic differences of Sjögren’s syndrome versus sicca syndrome in HCV and HIV infection. Arthritis Res. Ther. 2011;13:233–239. doi: 10.1186/ar3361. - DOI - PMC - PubMed

MeSH terms